Acadesine inhibits neutrophil CD11b up-regulation in vitro and during in vivo cardiopulmonary bypass  by Mathew, Joseph P. et al.
ACADESINE INHIBITS 
NEUTROPHIL CD11 B 
UP-REGULATION IN VITRO 
AND DURING IN VIVO 
CARDIOPULMONARY 
BYPASS 
From the Departments of Laboratory Medicine c 
and Anesthesiology, a Yale University 
School of Medicine and Yale-New Haven 
Hospital, and the Multicenter S udy of 
Perioperative Ischemia (McSP1) Research 
Group, b New Haven, Conn. 
Supported by National Institutes of H alth grant 
HL47193 (B.R.S.) and Gensia Pharmaceuti- 
cals. Christine Rinder is a recipient of a  
American Heart Association Clinician-Sci- 
entist Award, and Brian Smith is a Scholar 
of the Leukemia Society of America. 
Received for publication Feb. 10, 1994. 
Accepted for publication July 12, 1994. 
Address for reprints: Christine S. Rinder, MD, 
Department of Anesthesiology, Yale Uni- 
versity School of Medicine, P.O. Box 
208035, New Haven, CT 06520-8035. 
Copyright © 1995 by Mosby-Year Book, Inc. 
0022-5223/95 $3.00 + 0 12/1/59165 
Granulocyte adhesion to ischemie tissue, mediated in large part by /I 2 integrin 
receptors, is important in the pathophysiology of reperfusion i jury. Acadesine, a drug 
that modulates adenosine levels in ischemic tissue, has been shown to reduce reperfu- 
sion injury in animal models of ischemia. The purpose of this study was to measure 
changes in granulocyte CDllb/CD18 in an in vitro assay and in an in vivo trial of 
acadesine administered during cardiopulmonary b pass to determine whether this 
agent might modulate up-regulation fthis adhesion receptor. In vitro, whole blond was 
incubated with acadesine or control diluent, stimulated with N-formyl-methionyl-leucyl- 
phenylalanine, and granulocyte CDllb measured. Acadesine significantly (p < 0.01) 
inhibited N-formyl-methionyMeucyl-phenylalanine-induced granulocyte CDllb up-reg- 
ulation by a mean of 61%. In similar experiments, adenosine also inhibited N-formyl- 
methionyMeucyl-phenylalanine--induced granulocyte CDllb up-regulation (/7 < 0.01). 
In vivo, 34 patients at our institution participating in a multicenter trial of acadesine 
during cardiopulmonary b pass were randomized to placebo, low-dose, or high-dose 
acadesine infusion perioperatively. Combining low- and high-dose treatment groups, 
there was significant (p = 0.05) inhibition of granulocyte CDllb up-regulation in 
patients receiving acadesine; granulocyte CDllb expression in the acadesine group 
peaked at 2.8 times baseline versus 4.3 for placebo. By contrast, monocyte CDllb 
up-regulation (peaking after cardiopulmonary bypass at 3 times baseline) was not 
affected by acadesine. Acadesine and adenosine inhibit up-regulation of granulocyte 
CDllb in vitro, and acadesine is capable of a similar inhibition during in vivo 
cardiopulmonary bypass. This inhibition may contribute to the ability of these agents to 
decrease in vivo reperfusion i jury. (J THORAC CARDIOVASC SURG 1995;109:448-56) 
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A cadesine (5 amino-4 imidazole carboxamide ri- boside) is the first of a new group of drugs 
classified as adenosine-regulating agents whose ef- 
fects are thought to be mediated by increases in 
endogenous adenosine levels in ischemic myocardi- 
um. 1 In preclinical studies, acadesine has been 
shown to inhibit platelet aggregation, 2 improve post- 
ischemic ventricular contractile function, 3' 4 inhibit 
neutrophil (PMN) adherence to endothelium, 5 de- 
crease PMN accumulation i  ischemic myocardi- 
um, 6 and decrease free radical- and oxidant-induced 
cardiac damage] Mechanisms for acadesine's inhi- 
bition of PMN adhesion and respiratory burst, how- 
ever, have not been elucidated. CDlla/CD18 and 
CDllb/CD18 are members of the/32 integrin family 
of adhesion receptors. CDllb/CD18 in particular 
permits PMN adhesion to and diapedesis through 
endothelial cells, s-l° Adhesion of PMN via CDl lb/  
CD18 has been shown to be necessary for secretion 
of hydrogen peroxide in response to N-formyl- 
methionyMeucyl-phenylalanine (fMLP) or platelet- 
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activating factor. 11' 12 We therefore hypothesized 
that acadesine-mediated inhibition of up-regulation 
of CDllb/CD18 might be involved in both the 
inhibition of PMN accumulation and the suppres- 
sion of oxidative burst observed in the aforemen- 
tioned studies. 
We have previously measured changes in leuko- 
cyte and platelet adhesion receptors occurring dur- 
ing cardiopulmonary b pass (CPB). Specifically, we 
examined changes in the leukocyte adhesion recep- 
tor CDl lb  and demonstrated that PMN and mono- 
cyte CDl lb  were up-regulated threefold to fourfold 
by the end of CPB. 13 Similarly, we examined platelet 
P-selectin, a receptor that is expressed as a conse- 
quence of a-granule release and that binds activated 
platelets to leukocytes, and demonstrated both in- 
creased platelet surface expression of P-selectin 
induced by CPB 14 and increased platelet-leukocyte 
conjugate formation during CPB. 13 We and others 
have also demonstrated changes in the platelet 
adhesion receptors glycoprotein (GP)Ib and GPIIb/ 
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I I Ia but not GPIV during CPB. 15-19 For the current 
study we used an in vitro whole blood assay to 
measure changes in PMN CDl lb  occurring in re- 
sponse to N-formyl-methionyl-leucyl-phenylalanine 
after incubation with acadesine, adenosine, or con- 
trol diluent. In addition, in an in vivo study of 
acadesine during CPB, using techniques described 
previously, 13-15 we sought to determine whether 
acadesine affects either in vivo CPB-induced up- 
regulation of leukocyte adhesion receptors (PMN/ 
monocyte CD11b and/or CD11a) or platelet adhe- 
sion receptors (expression of P-selectin, platelet- 
leukocyte adhesion, and platelet GPIb). 
Materials and methods 
Materials. For in vitro studies, acadesine, adenosine, 
and fMLP were obtained from Sigma Chemical Co. (St. 
Louis, Mo.); diluents for these materials were phosphate- 
buffered saline solution for acadesine and adenosine and 
dimethyl sulfoxide for fMLP. Controls for all reagents in 
each experiment consisted of the appropriate final con- 
centration of diluent without agonist. For in vivo studies, 
acadesine was supplied by Gensia Pharmaceuticals (San 
Diego, Calif.) as part of its multicenter phase I1 and III 
trials. 
Antibodies. All monoclonal antibodies were used as 
purified whole immunoglobulin G. All experiments in- 
cluded irrelevant isotype-specific monoclonal antibodies 
as negative controls. The monoclonal ntibody 1E32° (gift 
of Dr. K. Ault, MCRI, So. Portland, Me.) is specific for 
P-selectin. P221 and SZ222 (AMAC, Inc., Westbrook, 
Me.) recognize platelet GPIIb/IIIa and GPIb, respec- 
tively. Anti-CD45 (HLE, Becton-Dickinson Immunocy- 
tometry Systems, San Jose, Calif.) is directed against an 
antigen present on PMNs, monocytes, and lymphocytes 
but neither erythroid cells nor platelets, a3 The monoclonal 
antibodies Dl224 (Leu-15, Becton-Dickinson) and RR3.1 
(gift of Dr. R. Rothlein, Boehringer-Ingelheim, Ridge- 
field, Conn.) recognize leukocyte CDllb and CDlla, 
respeetively. 
Fluoreseenee labeling. As previously detailed, all in 
vitro and in vivo whole blood samples were flxed for 60 
minutes at 4 ° C, then washed in Tyrode-HEPES bufferY 
Samples from in vitro experiments were studied for PMN 
CDllb only. Patient samples were divided into three 
aliquots for study: orte for the platelet receptors GPIb and 
P-selectin, one for the leukocyte adhesion receptors 
CDlla and CDllb, and one for the percentage of leuko- 
cyte-platelet conjugates. 
Leukocyte surface CDlla and CDllb were measured 
by incubating samples with saturating concentrations of
fluorescein isothiocyanate (FITC)-anti-CD45 and either 
biotinylated anti-CDlla or phycoerythrin-anti-CD11b. 
The samples incubated with anti-CDlla were washed and 
incubated with saturating concentrations of phycoerythrin- 
streptavidin (Becton-Dickinson). All samples were then 
washed and resuspended in Tyrode-HEPES buffer for fluo- 
rescence-aetivated c llsorter (FACS) analysis. 
For determination of the surface density of platelet 
GPIb, 100 /xl of sample was incubated with saturating 
concentrations of FITC-anti-GPIb, washed, and resus- 
pended in Tyrode-HEPES buffer for flow cytometric 
analysis as previously described) » To measure the per- 
centage of circulating platelets expressing P-selectin, we 
incubated a separate sample with FITC-anti-GPIIb/IIIa 
and biotinylated anti-P-selectin, 14 washed, and incubated 
with saturating concentrations of phycoerythrin-streptavi- 
din, washed, and resuspended in Tyrode-HEPES for 
FACS analysis. 
For the percentage of leukocyte-platelet conjugates, the 
third sample was incubated with FITC-anti-CD45 and 
biotinylated anti-GPIIb/IIIa, washed, and resuspended in 
Tyrode-HEPES buffer. Phycoerythrin-streptavidin label- 
ing and preparation for FACS analysis were performed as 
described earlier. 
Flow cytometry. Samples were analyzed on an 
FACScan flow cytometer (Becton-Dickinson, Mountain 
View, Calif.) with data stored in list mode files. The 
determination of the surface density of GPIb and the 
percentage of platelets expressing P-selectin was carried 
14 15 26 27 out as previously described. ' ' ' The determination 
of GPIb density always incorporated a single platelet gate 
using forward scatter to ensure that measurements of 
GPIb were not biased by microaggregate or micropartiele 
formation. Leukocyte surface CDlla and CDllb were 
measured by appropriate forward- versus side-scatter 
gates combined with CD45 expression to distinguish 
PMNs, monocytes, and lymphocytes. 25 Quantification of 
leukocyte-platelet conjugates was based on events that 
simultaneously f uoresced for both CD45 and GPIIb/IIIa 
as previously described. 13' 25 As noted earlier, isotype- and 
fluorochrome-matched control monoclonal antibodies 
were used in each experiment todeterrnine "nonspecific" 
background fluorescence. 
Leukocyte aetivation in vitro. All in vitro experiments 
were conducted in whole blood to minimize CDllb 
up-regulation associated with leukocyte purification. 28
Specifically, heparinized whole blood (final heparin con- 
centration 14 units/ml) was incubated with acadesine, 
adenosine, or diluent for 15 minutes at 37 ° C; the doses of 
acadesine and adenosine used have previously been 
shown to inhibit other functional changes in PMNs in in 
vitro experiments. 6' 29 Samples were then stimulated with 
fMLP for an additional 15 minutes at 37 ° C; preliminary 
experiments demonstrated maximal CDllb expression at 
this point after addition of fMLP. Samples were then 
removed irectly into 1% paraformaldehyde and exam- 
ined for the surface xpression of PMN CDllb. 
In vivo studies: Patient seleetion. Studies were per- 
formed on patients at Yale University who were enrolled 
in phase Il and phase III of multicenter trials of the 
myocardial protective ffects of acadesine (conducted by 
the Multicenter Study of Perioperative Ischemia Research 
Group); the clinical results of phase II have been previ- 
ously reported. 3°' 31 The current study was conducted as 
part of our ongoing investigation of adhesion receptors 
during CPB and used only patients studied at Yale 
University. After institutional approval by the Human 
Investigation Committee of the Yale University School of 
Medicine and informed consent, 34 conseeutive patients 
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undergoing elective coronary artery bypass grafting re- 
quiring CPB were studied. Patients excluded from the 
multicenter study included those with hemodynamically 
significant valvular disease, patients undergoing other 
procedures concurrent with the bypass operation, patients 
with recent or evolving myocardial infarction within 7 days 
before the operation, patients in cardiogenic shock, and 
patients with a history of uric acid nephropathy, hepatic 
insufficiency, or renal insufficiency. Pharmacologic exclu- 
sion criteria included the use of adenosine or pentoxifyl- 
line within 12 hours of the operation, theophylline and 
nicotinic acid within 24 hours of the operation, and 
dipyridamole within 48 hours of the operation. One 
additional patient was excluded from analysis in the 
present study because of a hematologic malignancy. 
Study protoeol. The 34 patients were randomized in 
double-blind fashion into a placebo group (n = 11), a 
group receiving low-dose acadesine (0.05 mg/kg per 
minute intravenously and 5 tzg/ml in cardioplegic solution, 
n = 11), and a group receiving high-dose acadesine (0.1 
mg/kg per minute intravenously and 5/zg/ml in cardiople- 
gie solution, n = 12). Acadesine or placebo was infused 
continuously beginning 15 minutes before induction of 
anesthesia nd for 7 hours thereafter. Anesthesia was 
induced and maintained with fentanyl and midazolam, 
both by bolus followed by infusion, and thiopental up to 7 
mg/kg. Blood pressure and heart rate were maintained 
within 20% of baseline values. CPB was conducted with a 
COBE CML membrane oxygenator (Cobe Laboratories, 
Inc., Denver, Colo.) and moderate systemic hypothermia 
(28 ° C). Whole blood samples (200 tzl) were taken from 
the radial artery catheter and immediately fixed in 
paraformaldehyde in phosphate-buffered saline solution 
(1% final concentration), as previously described) 2 Sam- 
ples were taken at the following times: before the start of 
acadesine infusion, at termination of CPB (before prota- 
mine), and 18 hours after CPB. Patient samples were 
studied for (1) leukocyte surface xpression ofCDlla and 
CDllb, (2) platelet activation (P-selectin expression), (3) 
platelet surface density of GPIb, and (4) percentage of
leukocyte-platelet eonjugates. CDlla and GPIb were 
studied only after initiation of phase III of the clinical 
trial, reducing the number of patients tudied to 22 for 
these receptors. An additional whole blood sample (1 ml) 
was drawn into ethylenediaminetetraacetic acid (5 mmol/L 
final concentration) at each of the aforementioned times and 
the total eukocyte count and differential were measured in 
all 34 patients with an automated Cotflter STKS counter 
(Coulter Electronics, Hialeah, Fla.). 
Statistical analysis. Data are expressed as mean + 
standard error of the mean (SEM). Measurements that 
compared the surface density of a receptor in serial 
samples on the same patient (e.g., CDlla, CDllb, GPIb) 
were normalized to the starting value. Measurements that 
looked at the percentage of positive cells, that is, those 
which bound monoclonal antibodies above baekground 
levels (P-selectin, platelet-PMN, and platelet-monocyte 
conjugates), were expressed as a percentage of the total 
number of cells tested per sample. In vitro and demo- 
graphic data were analyzed by the t test for independent 
samples to determine whether there was an effect of the 
drug and by analysis of variance to identify any dose- 
dependency. For in vivo data, groups were compared by 
two-factor repeated-measures analysis of variance, where 
group and time were the factors, with repeats on the time 
factor. A value of p -< 0.05 was considered statistically 
significant. 
Results 
In vitro ieukoeyte activation. Samples of whole 
blood incubated with acadesine or diluent were 
stimulated with four doses of fMLP and examined 
for changes in PMN CDl lb.  In diluent-treated 
samples, fMLP resulted in a PMN CDl lb  increase 
of 1.5-, 1.6-, 1.7-, and 1.8-fold at doses of 5, 10, 50, 
and 100 nmol/L respectively. As shown in Fig. 1, A, 
acadesine preincubation produced a significant in- 
hibition (t9 < 0.01) of the upregulation in PMN 
CDl lb  induced by fMLP as compared with diluent- 
treated cells (acadesine doses: 1 mmol/L, 500 
/xmol/L, and 100/zmol/L), and this effect was dose- 
related (p < 0.05). By examining the fluorescence 
histograms of CDl lb  binding, we found that the 
inhibition of CDl lb  was uniformly distributed 
among all PMNs; that is, no PMN subset was 
disproportionately affected by acadesine. 
Whole blood samples were similarly incubated 
with adenosine or diluent and stimulated with three 
doses of fMLP as shown in Fig. 1, B. Like acadesine, 
adenosine demonstrated significant (p < 0.01) inhi- 
bition of PMN CDl lb  up-regulation i response to 
fMLP; this effect was dose-related (p < 0.05) and, as 
with acadesine, affected the entire PMN population. 
In vivo studies 
Demographics. Twenty-eight men and six women 
were studied, averaging 62 years of age. There was 
no difference between placebo, low-dose, and high- 
dose acadesine groups in either the sex or age 
distribution. Average CPB time in the pla¢ebo 
group was 87 -- 10 minutes (mean _+ SEM), which 
was significantly shorter (p = 0.02) than that of the 
low-dose acadesine group (117 _+ 6 minutes) and 
not different from that of the high-dose acadesine 
group (107 + 12 minutes). Similarly, the crossclamp 
time was significantly shorter (p = 0.05) in the 
placebo group (49 --_ 5 minutes) than in the low-dose 
acadesine group (63 ___ 4 minutes) but not the high- 
dose acadesine group (59 -+ 7 minutes). When both 
acadesine treatment groups were combined, the total 
bypass time was still significantly longer than pla- 
cebo (p = 0.05), but crossclamp time was not 
significantly longer than placebo (p = 0.08). 
Monocyte and PMN activation. In placebo-treated 
patients, surface xpression of CDl lb  on monocytes 
increased significantly (p < 0.01) during and after 
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Fig. 1. Percentage inhibition of PMN CDllb up-regulation. Heparinized whole blood was incubated with 
acadesine (A), adenosine (B), or control diluent, followed by stimulation with fMLP (15 minutes) at the 
doses hown on the x-axis. Samples were labeled with monoclonal ntibodies toCDllb as described inthe 
Materials and methods ection and mean CDllb fluorescence on PMN was measured. All CDllb 
fluorescence values were normalized to control CDllb (diluent incubation followed by fMLP). Values 
shown represent the mean +_ SEM for three experiments. Both acadesine and adenosine significantly 
inhibited CDllb up-regulation in response to fMLP (p < 0.01), and this effect was dose-related (p < 0.05). 
CPB, peaking 18 hours after termination of bypass 
at 3 times the baseline value. CD11b expression on 
PMN also rose significantly in the placebo group 
(p < 0.01) to a value 4 times baseline, but, unlike 
monocytes, PMN CDllb peaked earlier (at termi- 
nation of CPB) and remained elevated 18 hours 
after CPB at approximately 2.5 times baseline. 
When treatment groups were compared with pa- 
tients receiving placebo for increases in CDllb 
expression using two-factor analysis of variance, 
there was no difference in the increase in monocyte 
CDllb in the two treatment groups when examined 
singly as compared with the placebo group. Simi- 
larly, the changes in PMN CDllb in the acadesine 
treatment groups when examined singly did not 
reach statistical significance (p = 0.16). However, 
when low- and high-dose treatment groups were 
combined and compared with the placebo group, 
there was a significant (p = 0.05) blunting of the 
PMN CD11b up-regulation i duced by CPB in the 
acadesine group (Fig. 2, A). PMN CDllb expres- 
sion in the treatment group peaked at 2.8 +_ 0.3 
(mean + SEM) times baseline values, as compared 
with 4.3 +_ 0.9 (mean +_ SEM) times baseline for the 
placebo group. Increases in monocyte CDllb re- 
mained unaffected by acadesine treatment when 
high- and low-dose treatment groups were com- 
bined (Fig. 2, B). 
Surfaee xpression of CDl la was similarly exam- 
ined on PMN and monocytes (Fig. 3) and was found 
in the placebo group to increase significantly (p < 
0.01) during CPB only on monocytes. Monocyte 
CDl la expression i creased to 1.5 _+ 0.2 (mean + 
SEM) times baseline at termination of CPB and 
increased further to 2.2 +_ 0.3 (mean + SEM) times 
baseline 18 hours after CPB. However, there was no 
difference in CD11a up-regulation i  monocytes for 
acadesine groups when analyzed singly versus the 
placebo group or after combination of the low- and 
high-dose treatment groups. 
The number of circulating PMNs increased 
slightly during CPB and continued to increase 18 
hours after CPB in all patients (Table I). The com- 
bined low- and high-dose treatment groups demon- 
strated a higher PMN count; however, the difference 
did not reach statistical significance (p = 0.14). The 
absolute number of monocytes was similarly unaf- 
fected by acadesine treatment, whether groups were 
examined singly or low- and high-dose treatment 
groups were combined. 
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Fig. 2. Leukocyte CDllb on CPB. Total surface CDllb was measured on PMNs (A) and monocytes (B) 
in whole blood taken before the operation (Baseline), at termination ofCPB (End CPB), and 18 hours after 
CPB (18 hrs post CPB) and is expressed as a percentage of the baseline fluorescence value. Patients 
receiving placebo are shown in solid circles (n = 11) and patients receiving low- or high-dose acadesine in
the open triangles (n = 23). Each measurement is he mean - SEM. Up-regulation of PMN CDllb was 
significantly inhibited by acadesine treatment when compared with placebo (p = 0.05). Increases in 
monocyte CDllb were not affected by acadesine treatment (p = 0.55). 
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Fig. 3. Leukocyte CDlla on CPB. Total surface CDlla was measured on PMNs (A) and monocytes (B) 
in whole blood, as described in Fig. 2, and similarly divided into a placebo group (solid circles) and 
acadesine-treated group (open triangles). Only monocyte CDlla increased significantly (p = 0.01) in both 
the placebo group and acadesine-treated patients, and there was no difference in CDllb expression 
between these two groups (p = 0.73). 
Platelet adhesion receptors (P-selectin and GPIb 
modulation). The percentage of circulating platelets 
expressing surface P-selectin increased significantly 
in all patients (p < 0.05) by termination of CPB and 
into the post-CPB period (data not shown), as has 
been previously reported. 13-15 Similarly, surface ex- 
pression of the von Willebrand factor adhesion 
receptor, GPIb, decreased significantly in all pa- 
tients (p < 0.01) 18 hours after CPB to 86% --_ 1.7% 
(mean + SEM) of baseline values. 1»' 16, 18 The in- 
creased in P-selectin expression and the decrease 
in GPIb did not differ between any of the groups 
when analyzed singly or when low- and high-dose 
acadesine groups were combined. 
Platelet-leukocyte adhesion. For the 34 patients 
taken as a single group, the percentage of leukocytes 
with bound platelets was comparable between leu- 
kocyte subsets before the start of the operation, with 
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Table I. Mean PMN counts +__ SEM 
Baseline End CPB 18 hr after CPB p Value* 
PMNs (X 106/ml) 
Placebo 
Low + high 
Monocytes (x  106/ml) 
Placebo 
Low + high 
3.91 + 0.45 5.69 +- 1.01 7.94 +-_ 1.32 0.14 
4.02 + 0.34 7.29 -+ 0.93 10.5 + 0.91 
0.55 ± 0.07 0.35 ± 0.08 0.80 + 0.17 0.58 
0.59 + 0.05 0.35 ± 0.06 0.92 - 0.07 
*For placebo versus low + high. 
16% _+ 1.9% (mean + SEM) of monocytes and 
11% +_ 1.3% of PMNs binding platelets. These 
values are similar to those previously described. 13
The percentage of circulating monocyte-platelet 
conjugates increased significantly in all groups, 
peaking at the end of CPB with a mean of 40% _+ 
3.3% (SEM) of circulating monocytes having bound 
platelets (p < 0.01). The percentage of circulating 
PMN-platelet conjugates also increased significantly 
in all patients at termination of CPB (p < 0.05), but 
to a much lower percentage (15% + 1.6% SEM) 
than monocytes. There was no difference in the 
degree of platelet-leukocyte adhesion for either 
leukocyte subset in the treatment groups when 
analyzed either singly or in combination versus the 
placebo group. 
Discussion 
In this investigation we have demonstrated in
vitro that both acadesine and adenosine are capable 
of significantly inhibiting the increase in PMN 
CD11b indueed by the PMN agonist fMLP. This in 
vitro observation is supported by the in vivo dem- 
onstration that acadesine similarly inhibits the up- 
regulation of PMN CD11b during CPB. This effect 
appears speeific for CDl lb and for granulocytes 
(PMN CD11a and monocyte CD11a and CD11b 
were not affected). 
CD11a/CD18 and CD11b/CD18 are members of 
the/32 integrin family of adhesion receptors, which 
have a common /3-subunit (CD18) and a distinct 
o~-subunit (CD11a, CDllb, CDllc). CDlla/CD18 
and CDllb/CD18 in particular permit PMN adhe- 
sion to and diapedesis through endothelial cells, s-l° 
PMN CD11b/CD18-mediated adhesion is necessary 
for hydrogen peroxide secretion in response to the 
PMN agonists fMLP and platelet-activating fac- 
tor.il, 12 In animal models of myocardial and lung 
injury, antibodies to CD11b have been shown to 
attenuate the injury associated with infarction and 
reperfusion33, 34or eomplement infusionY In hu- 
man beings, CDl lb has been shown to be up- 
regulated in PMNs and monocytes across the coro- 
nary circulation in patients with unstable angina. 36 
Thus CD11b/CD18 up-regulation may result from, 
as well as contribute to, tissue damage induced by 
ischemia. By contrast, PMN CDlla/CD18 appears 
to be more important in the adhesion of resting 
PMNs to activated endothelial cells. CDl la  surface 
expression is not changed in response to chemotac- 
tic stimulation 37 or, as demonstrated in this study, by 
PMN activation occurring during CPB. 
Adenosine has been shown in vitro to inhibit both 
fMLP-induced superoxide radical formation by 
PMNs and PMN adhesion to endothelial cells. 38' 39 
These effects have been shown to correlate with a 
reduction in infarct size in animal models of myo- 
cardial infarction and reperfusion i n ju ry .  40'41 
Acadesine is a purine nucleoside analog that has 
been classified as an "adenosine-regulating agent" 
because of its capacity to increase adenosine accu- 
mulation in tissues where ischemia drives cells to net 
adenosine triphosphate catabolism. 1 By increasing 
endogenous adenosine levels locally, acadesine has 
been shown to improve postischemic ontractile 
function, increase subendocardial blood flow with- 
out inducing coronary steal, augment myocardial 
preconditioning, attenuate myocardial stunning, and 
decrease granulocyte accumulation i ischemic myo- 
cardium.1, 3These effects have been shown to cor- 
relate with a reduction in infarct size in animal 
models of myocardial infarction and reperfusion 
injury.4, 6 
We 13 have previously reported that CPB results in 
significant up-regulation of CDl lb on both PMNs 
and monocytes in the systemic circulation, and 
comparable degrees of CDl lb up-regulation were 
found in the placebo group in the current study. 
Patients in the present study were also studied for 
changes in CDlla, but, as mentioned earlier, only 
monocytes demonstrated a significant increase in 
this adhesion receptor. The specific agent(s) respon- 
sible for this increase are not known, but candidates 
include intermediaries in the complement and con- 
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tact activation pathways, both of which are activated 
by CPB. 42' 43 The in vivo arm of this study was 
conducted on patients at out institution who were 
enrolled in multicenter phase II and III trials of 
acadesine. As noted in the preliminary report of 
phase II of the multicenter study, acadesine pro- 
duced a 64% reduction in myocardial infarction 
(defined by both the appearance ofde novo Q waves 
and an increase in the levels of the myocardial [MB] 
fraction of creatine kinase). 3°' 31 When low and high 
doses were combined from all institutions, the 
acadesine-treated patients had a lower incidence 
(29%) of creatine kinase MB spillage than the 
placebo group (47%), withp = 0.05. The blunting of 
PMN CDl lb up-regulation by in vivo acadesine, 
which we have demonstrated in our rauch smaller 
number of patients, was unexpected in view of the 
fact that acadesine has been thought o have local- 
ized effects under conditions of tissue ischemia 
resulting in adenosine triphosphate catabolism, but 
not necessarily systemic effects. However, our in 
vitro studies demonstrate hat in whole blood under 
normoxic onditions, acadesine is capable of inhib- 
iting the increases in CDl lb induced by fMLP. 
Acadesine would seem to offer significant advan- 
tages over adenosine, because in the therapeutic 
range acadesine is associated with minimal effects 
on cardiac conduction and vascular tone. 44' 45 Pa- 
tients receiving acadesine demonstrated higher total 
PMN counts on average, perhaps resulting from 
their lower surface expression of adhesion recep- 
tors; however, this difference was not statistically 
significant in the current study. 
Both acadesine and adenosine demonstrated 
dose-related in vitro inhibition of CDIlb upregula- 
tion. The dose-responsiveness wa seen at doses that 
varied by fivefold and tenfold. The lack of apparent 
dose-responsiveness ob erved in vivo is likely due to 
the relatively small numbers of patients studied 
together with the fact that low- and high-dose 
treatment groups differed by only a factor of 2. The 
inhibition of myocardial ischemia measured in 
phase II of the study was also not dose-related, 31 but 
phase III demonstrated a reduction in infarction 
incidence and creatine kinase MB release in patients 
having Q waves at the higher dose (D. Mangano and 
the Multicenter Study of Perioperative Ischemia 
Research Group, personal communication). 
Both adenosine and acadesine have been shown 
to inhibit platelet aggregation i  previous in vitro 
studies, z'46 We hypothesized that this inhibitory 
effect might result from inhibition of platelet gran- 
ule release, comparable with the inhibition of 
CDl lb up-regulation from its preformed stores. We 
measured changes in platelet expression of P-selec- 
tin and GPIb, as well as P-selectin-dependent plate- 
let-leukocyte adhesion during CPB, to determine 
whether acadesine might exert an inhibitory effect 
on platelet adhesion receptors in vivo. Acadesine 
did not inhibit P-selectin expression, loss of GPIb, or 
the increase in P-selectin-dependent platelet-leuko- 
cyte conjugate formation induced by CPB. This 
suggests that the effects of acadesine during CPB are 
relatively specific for inhibition of PMN activation, 
as opposed to a more general suppression of cellular 
activation. 
PMNs have been increasingly implicated in the 
pathophysiology of myocardial infarction and reper- 
fusion injury. 47' 48 Advances in thrombolytic therapy 
and balloon angioplasty have spurred efforts to 
inhibit PMN-mediated tissue injury and thereby 
salvage newly reperfused myocardium. The current 
study implicates direct inhibition of up-regulation of 
the adhesion receptor, CDllb, by adenosine and 
acadesine as one possible mechanism for their abil- 
ity to prevent PMN-mediated injury in myocardial 
ischemia. 
We thank the Multicenter Study of Perioperative Isch- 
emia Research Group, which conducted the phase II and 
III acadesine trials. 
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